TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00784407

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: harmonic scalpel device utilized intraoperatively
Description: harmonic scalpel device utilized intraoperatively (FOCUS in group A and HARMONIC ACE in group B patients)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: harmonic scalpel device utilized intraoperatively
Description: harmonic scalpel device utilized intraoperatively (FOCUS in group A and HARMONIC ACE in group B patients)
Study: NCT04024761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is a chemotherapy agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (CP), also known as cytophosphane among other names, is a chemotherapy agent
Study: NCT00835536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin 200 mg tablets
Description: 1 x 200 mg, single-dose non-fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COPEGUS™ 200 mg Tablets
Description: 1 x 200 mg, single-dose non-fasting
Study: NCT01794845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erbitux
Description: Erbitux: 400 mg/m2 as a loading dose one week prior to radiation and taxotere, and then at 250 mg/m2 given weekly on Day 1 of treatment week following Taxotere.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: Taxotere : 20 mg/m2 IV once a week on Day 1 during treatment weeks 2 to 7.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low Dose Fractionated Radiation Therapy
Description: Low-dose fractionated Radiation (LDFRT): 0.5 Gy per fraction twice-a-day (BID) at least 6 to 8 hours apart on Days 2 and 3 of treatment weeks 2 to 7 for a total dose of 12 Gy.
Study: NCT01359696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0425
Description: Oral escalating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Intravenous repeating dose
Study: NCT01255085

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: yellow pea protein
Description: Served in a tomato soup

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: yellow pea protein
Description: Served in a tomato soup

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: yellow pea fiber
Description: Served in a tomato soup

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: yellow pea fiber
Description: Served in a tomato soup

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control Tomato Soup
Description: Served in a tomato soup
Study: NCT03733730

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACRYSOF IQ RESTOR +3.0 Multifocal Toric IOL
Description: Intraocular lens (IOL) intended for visual correction of aphakia in adult patients with and without presbyopia, who desire near, intermediate and distance vision, reduction of residual cylinder and increased spectacle independence. IOLs are implantable medical devices and are intended for long term use over the lifetime of the cataract subject.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACRYSOF IQ RESTOR +3.0 Multifocal Toric IOL
Description: Intraocular lens (IOL) intended for visual correction of aphakia in adult patients with and without presbyopia, who desire near, intermediate and distance vision, reduction of residual cylinder and increased spectacle independence. IOLs are implantable medical devices and are intended for long term use over the lifetime of the cataract subject.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACRYSOF IQ RESTOR +2.5 D Multifocal Toric IOL
Description: Intraocular lens (IOL) intended for visual correction of aphakia in adult patients with and without presbyopia, who desire near, intermediate and distance vision, reduction of residual cylinder and increased spectacle independence. IOLs are implantable medical devices and are intended for long term use over the lifetime of the cataract subject.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACRYSOF IQ RESTOR +2.5 D Multifocal IOL
Description: Intraocular lens (IOL) intended for visual correction of aphakia in adult patients with and without presbyopia, who desire near, intermediate and distance vision with increased spectacle independence. IOLs are implantable medical devices and are intended for long term use over the lifetime of the cataract subject.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract Surgery
Description: Routine small incision cataract surgery with IOL implantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract Surgery
Description: Routine small incision cataract surgery with IOL implantation
Study: NCT02311686

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10 g ethanol
Description: Alcohol single oral dose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 20 g ethanol
Description: Alcohol single oral dose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 40 g ethanol
Description: Alcohol single oral dose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 60 g ethanol
Description: Alcohol single oral dose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 80 g ethanol
Description: Alcohol single oral dose
Study: NCT03100344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemolizumab
Description: Injection every 4 weeks during 24 weeks (last injection at week 20)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemolizumab
Description: Injection every 4 weeks during 24 weeks (last injection at week 20)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemolizumab
Description: Injection every 4 weeks during 24 weeks (last injection at week 20)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection every 4 weeks during 24 weeks (last injection at week 20)
Study: NCT01795872

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Several diagnostic procedures
Description: No drug will be assigned, diagnostic assessment within the study.
Study: NCT04402151

Intervention type: DRUG
Group type: OTHER
Intervention: PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC
Description: Patients enrolling on the protocol will undergo prostate-specific membrane antigen (PSMA) Positron Emission Tomography (PET)/Magnetic Resonance(MR) prior to start of the radiation treatment planning process. PSMA tracer is administered by IV injection and PET images are acquired.~Any patients found to have possible metastatic disease will undergo a standard of care confirmatory biopsy (if feasible) and receive treatment appropriate for their stage.~The PSMA PET/MR scan will be performed prior to initiation of androgen deprivation therapy (ADT).

Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Patients will receive standard of care radiation therapy (SBRT)
Study: NCT01686451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XueZhiKang
Description: Participants will receive 600mg of XueZhiKang twice a day for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: Participants will receive 20mg of simvastatin daily for 4 weeks.
Study: NCT00130377

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cell therapy
Description: autologous or allogeneic cells

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: cell therapy
Description: autologous or allogeneic cells
Study: NCT02377778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol intravenous infusion for introduction and maintance of anaesthesia at doses 3-5mg depending on the total time needed for completion of oocyte retrieval

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiopental
Description: Patients will receive thiopental in addition to fentanyl for introduction and maintanance of anaesthesia at doses 7mg. IF required patients will receive a repeat dose of 1-3mg of thiopental depending on the totla time needed to complete oocyte retrieval
Study: NCT03647254

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient education group
Description: Group meetings with educational sessions will be organised in health center. A group educational intervention was practiced to half of the patients, by one expert patient, so that every patient must attend to one group meeting
Study: NCT01998295

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether/lumefantrine
Description: Medication was given at 0, 8, 24, 36, 48 and 60 hours. Food was given to all patients prior to medication to ensure proper absorption of the drug.
Study: NCT03423485

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CG-100 Intraluminal Bypass Device
Description: Intended to reduce contact of fecal content with an anastomotic site , following colorectal surgery.
Study: NCT02470247

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (RIPC)
Description: RIPC is accomplished by performing 4 cycles of alternating 5-minute inflation and 5-minute deflation of a standard upper-arm blood pressure cuff, to induce transient and repetitive arm ischemia and reperfusion.~RIPC will be started just before the CTA, and the time between the last inflation cycle and the beginning of the CTA will be less than 45 minutes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: SHAM Remote Ischemic Preconditioning (SHAM RIPC)
Description: The SHAM Remote Ischemic Preconditioning (SHAM RIPC) will be carried out with the same number of cycles that the RIPC but cuff will be inflated to the diastolic pressure of the subject and the cuff will be deflated to10 mmHg in order to maintain a non- ischemic compression (blind patient protocol).
Study: NCT01850173

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A vertical vibration platform Fitybe
Description: They performed 6 series, and each series consisted of four 30-second repetitions with a frequency of 35 Hz and 2 millimeters of amplitude, with 60 seconds of rest between each series.
Study: NCT04553133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07104091 monotherapy dose escalation
Description: PF-07104091 will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07104091 + palbociclib + fulvestrant
Description: PF-07104091 will be administered orally in combination with palbociclib and fulvestrant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07104091 + palbociclib + letrozole
Description: PF-07104091 will be administered orally in combination with palbociclib and letrozole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07104091 monotherapy dose expansion (ovarian)
Description: PF-07104091 will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07104091 monotherapy dose expansion (SCLC)
Description: PF-07104091 will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07104091 + Fulvestrant (post CDK4/6)
Description: PF-07104091 will be administered orally in combination with fulvestrant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-0704091 + Fulvestrant (post CDK4/6)
Description: PF-07104091 + fulvestrant (post 4/6) dose expansion
Study: NCT06115291

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smell Test
Description: Oils are used for each of the different scents. Each scent is administered via an aromatherapy inhaling stick.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smell Test
Description: Oils are used for each of the different scents. Each scent is administered via an aromatherapy inhaling stick.
Study: NCT02008097

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GE LOGIQ E9 Ultrasound System
Description: Subjects will have an ultrasound exam using the GE LOGIQ E9 Ultrasound System which has computer software that combines the color-flow image and B-mode image to produce the new B-Flow method of ultrasound.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GE LOGIQ E9 Ultrasound System
Description: Subjects will have an ultrasound exam using the GE LOGIQ E9 Ultrasound System which has computer software that combines the color-flow image and B-mode image to produce the new B-Flow method of ultrasound.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GE LOGIQ E9 Ultrasound System
Description: Subjects will have an ultrasound exam using the GE LOGIQ E9 Ultrasound System which has computer software that combines the color-flow image and B-mode image to produce the new B-Flow method of ultrasound.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GE LOGIQ E9 Ultrasound System
Description: Subjects will have an ultrasound exam using the GE LOGIQ E9 Ultrasound System which has computer software that combines the color-flow image and B-mode image to produce the new B-Flow method of ultrasound.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GE LOGIQ E9 Ultrasound System
Description: Subjects will have an ultrasound exam using the GE LOGIQ E9 Ultrasound System which has computer software that combines the color-flow image and B-mode image to produce the new B-Flow method of ultrasound.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GE LOGIQ E9 Ultrasound System
Description: Subjects will have an ultrasound exam using the GE LOGIQ E9 Ultrasound System which has computer software that combines the color-flow image and B-mode image to produce the new B-Flow method of ultrasound.
Study: NCT04415515

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RN case management
Description: A Registered Nurse (RN) case manager makes phone contact with the member to review medications, health risks, care gaps/barriers, \& to develop a case management plan that focuses on improving medication adherence \& reconciliation, condition-based measures \& outcomes, addressing psycho-social needs, \& intensive post-admission care transition. RNs may refer the member to social workers,specialist providers, \& support programs (including to more intense case management where the primary care physician is notified that RNs may contact them to support treatment \& coordinate services).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker Case Management
Description: In selected UHC markets for defined time periods, members randomized to the treatment arm also received an enhanced version of the SCC that included in-home case management support from non-clinical Community Health Workers (CHW).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RN Standard care coordination and disease management
Description: RN Standard care coordination and disease management

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RN Standard care coordination and disease management
Description: RN Standard care coordination and disease management
Study: NCT01379209

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: According to institutional guidelines

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: According to institutional guidelines

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: According to institutional guidelines

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: According to institutional guidelines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mofetil Mycophenolate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mofetil Mycophenolate
Study: NCT01812525

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaCl 3%
Description: NaCl 3%: 4ml QID

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Standard therapy includes suctioning nasal secretions, water-electrolyte balance maintenance and oxygen supplementation when needed
Study: NCT01379209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mofetil Mycophenolate
Study: NCT01812525

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard therapy
Description: Standard therapy includes suctioning nasal secretions, water-electrolyte balance maintenance and oxygen supplementation when needed
Study: NCT01379209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mofetil Mycophenolate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mofetil Mycophenolate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mofetil Mycophenolate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mofetil Mycophenolate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mofetil Mycophenolate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Administered for GVHD prophylaxis as per institutional guidelines
Study: NCT04673994

Intervention type: BEHAVIORAL
Intervention: Single, acute bout of high intensity interval exercise
Description: Individuals will perform a single bout of high intensity interval exercise on a seated recumbent stepper. Participants will perform the pattern of high intensity interval exercise by switching between 1-minute high intensity stepping followed by 1-minute light, active recovery stepping for a total of 10 minutes.
Study: NCT01379209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Administered for GVHD prophylaxis as per institutional guidelines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Administered for GVHD prophylaxis as per institutional guidelines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Administered for GVHD prophylaxis as per institutional guidelines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Administered for GVHD prophylaxis as per institutional guidelines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Administered for GVHD prophylaxis as per institutional guidelines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Administered for GVHD prophylaxis as per institutional guidelines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Administered for GVHD prophylaxis as per institutional guidelines
Study: NCT01565551

Intervention type: OTHER
Intervention: N/A (Observational Study)
Description: No Interventions: Observational Study

Intervention type: OTHER
Intervention: N/A (Observational Study)
Description: No Interventions: Observational Study
Study: NCT04379180

Intervention type: DRUG
Intervention: Bosentan Tablets
Description: 2mg/kg, bid

Intervention type: DRUG
Intervention: Sildenafil Tablet
Description: 1mg/kg, q6h/q8h

Intervention type: DRUG
Intervention: Tadalafil Tablets
Description: 1mg/kg, qd
Study: NCT02894138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alteplase

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01837303

Intervention type: PROCEDURE
Intervention: Pap smear
Description: A pap smear/cervical cytology is performed using a spatula and brush to obtain cells from the ectocervical and endocervical region of the cervix. The specimen will be collected twice to put in the standard clinical pap medium and another to put in the study pap medium.~These slides will be processed so that they may be reviewed by a single board certified pathologist.~There are no other interventions or follow up. All participants will undergo the above described procedures. There is no placebo.
Study: NCT02038842

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LIPO-5
Description: LIPO-5: 1mL IntraMuscular, 2 shots;

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LIPO-5
Description: LIPO-5: 1mL IntraMuscular, 2 shots;

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LIPO-5
Description: LIPO-5: 1mL IntraMuscular, 2 shots;

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA HIV-B (MVATG17401)
Description: MVA HIV-B (MVATG17401): 0.5mL IntraMuscular, 2 shots;

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA HIV-B (MVATG17401)
Description: MVA HIV-B (MVATG17401): 0.5mL IntraMuscular, 2 shots;

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA HIV-B (MVATG17401)
Description: MVA HIV-B (MVATG17401): 0.5mL IntraMuscular, 2 shots;

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GTU®-MultiHIV B: 0.5 mL IM via Biojector® 2000 and 0.5mL IntraDermic, 3 shots
Description: GTU®-MultiHIV B: 0.5 mL IM via Biojector® 2000 and 0.5mL IntraDermic, 3 shots

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GTU®-MultiHIV B: 0.5 mL IM via Biojector® 2000 and 0.5mL IntraDermic, 3 shots
Description: GTU®-MultiHIV B: 0.5 mL IM via Biojector® 2000 and 0.5mL IntraDermic, 3 shots
Study: NCT03536377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: very low calorie liquid diet
Description: Phase 1: very low calorie liquid formulation Phase 2: Nutritionally balanced solid diet Phase 3: Educational material
Study: NCT00515190

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1,oxaliplatin
Description: Arm A (continuous arm): S-1 80mg/m2/d p.o. twice daily(q 12-h)on D1(evening)-D15(morning)plus oxaliplatin 130mg/m2 IV(in the vein)on D1 every 3 weeks, until disease progression, unacceptable toxicity, or consent withdrawal.~Arm B (intermittent arm):Treatment will be stopped after the initial 6 cycles of S-1 plus oxaliplatin, and then S-1 plus oxaliplatin will be resumed at the disease progression during follow-up, as the same dose as the last chemotherapy of initial 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1,oxaliplatin
Description: Arm A (continuous arm): S-1 80mg/m2/d p.o. twice daily(q 12-h)on D1(evening)-D15(morning)plus oxaliplatin 130mg/m2 IV(in the vein)on D1 every 3 weeks, until disease progression, unacceptable toxicity, or consent withdrawal.~Arm B (intermittent arm):Treatment will be stopped after the initial 6 cycles of S-1 plus oxaliplatin, and then S-1 plus oxaliplatin will be resumed at the disease progression during follow-up, as the same dose as the last chemotherapy of initial 6 cycles.